Global Angioplasty Balloons Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Angioplasty Balloons Market Analysis

The angioplasty balloons market is experiencing significant growth due to the rising prevalence of cardiovascular diseases, particularly coronary artery diseases, and the increasing demand for minimally invasive procedures. These balloons play a crucial role in percutaneous coronary interventions (PCIs) for expanding narrowed or blocked arteries, allowing for improved blood flow. The market growth is further driven by the growing aging population, which is more susceptible to heart-related conditions, and the increasing awareness of early diagnosis and treatment.

Technological advancements in angioplasty balloon designs, such as drug-eluting balloons (DEBs) and cutting-edge materials that improve the efficacy and safety of the procedures, are also contributing to market expansion. These innovations offer improved patient outcomes by reducing restenosis rates and enhancing balloon compliance.

Moreover, the growing preference for minimally invasive treatments, driven by factors like shorter recovery times, lower risk of complications, and reduced healthcare costs, is driving demand for angioplasty balloons. The development of balloons with advanced features, such as high-pressure and non-compliant balloons for more complex procedures, is expanding the scope of these devices in treating various cardiovascular conditions. Overall, the angioplasty balloons market is set to continue growing as advancements in technology, increased disease burden, and the shift toward minimally invasive treatments drive demand.

Angioplasty Balloons Market Size

The global angioplasty balloons market size was valued at USD 3.12 billion in 2024 and is projected to reach USD 4.38 billion by 2032, with a CAGR of 4.30% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Angioplasty Balloons Market Trends

“Growing Adoption of Drug-Eluting Balloons”

A key trend in the angioplasty balloons market is the growing adoption of drug-eluting balloons (DEBs). This trend is driven by the need to improve treatment outcomes and reduce restenosis rates in patients undergoing angioplasty procedures. DEBs are coated with medication that helps prevent the re-narrowing of arteries by releasing the drug directly at the site of the blockage. This localized drug delivery approach provides a more targeted and effective treatment compared to traditional bare-metal balloons. The trend toward DEBs is gaining momentum due to their ability to reduce the need for additional stent implantation and minimize the risk of complications such as vessel re-blockage. As a result, DEBs are increasingly being used in both coronary and peripheral vascular procedures. The growing preference for DEBs is largely driven by their improved efficacy in preventing restenosis, which is a major concern in angioplasty, making them a popular choice among healthcare professionals and patients alike.

Report Scope and Angioplasty Balloons Market Segmentation

Angioplasty Balloons Market Definition

Angioplasty is a procedure to improve blood flow in coronary arteries that have become narrow or blocked. Angioplasty balloons are medical devices used in percutaneous coronary interventions (PCIs) to treat narrowed or blocked blood vessels, particularly in the coronary arteries. These balloons are typically inserted into the affected artery through a catheter and inflated to expand the artery, restoring normal blood flow. Angioplasty balloons come in different types, including non-compliant balloons, which maintain their size when inflated, and compliant balloons, which expand with pressure. Drug-eluting balloons (DEBs) are another variation, coated with medication to reduce the risk of restenosis (re-narrowing of the artery). Angioplasty balloons play a vital role in minimally invasive heart surgeries, offering a less invasive alternative to open-heart surgery.

Angioplasty Balloons Market Dynamics

Drivers

• Increasing Prevalence of Cardiovascular Diseases

The growing incidence of cardiovascular diseases (CVDs) is a major driver of the angioplasty balloons market. CVDs, including coronary artery diseases (CAD), are a leading cause of death worldwide, with factors such as aging, unhealthy lifestyles, and poor dietary habits contributing to the rise in these conditions. Angioplasty balloons are essential in treating blocked or narrowed arteries caused by CAD, and their demand is rising as more people require interventional procedures like percutaneous coronary interventions (PCIs). For instance, in 2020, the World Health Organization (WHO) reported that CVDs accounted for 32% of global deaths, fueling the demand for medical devices like angioplasty balloons to address this health crisis. As the number of CVD patients grows, the market for angioplasty balloons continues to expand, particularly with the increasing adoption of minimally invasive treatment options.

• Advancements in Balloon Technology and Drug-Eluting Balloons (DEBs)

Technological advancements in angioplasty balloon designs have significantly contributed to market growth. The development of drug-eluting balloons (DEBs), which release medication to prevent restenosis, has been a game-changer. DEBs offer improved clinical outcomes by reducing the chances of the artery narrowing again after the procedure, making them particularly beneficial for patients with high restenosis risk. In addition, innovations such as high-pressure and non-compliant balloons have improved the safety and efficacy of angioplasty procedures. For instance, companies like Medtronic and Boston Scientific have pioneered DEBs, which have been used successfully in both coronary and peripheral artery interventions, improving patient outcomes and reducing the need for repeat surgeries. This technological innovation is pushing the angioplasty balloons market to new heights, as more healthcare providers adopt advanced treatment options.

Opportunities

• Growing Demand for Minimally Invasive Procedures

The increasing preference for minimally invasive procedures presents a significant opportunity for the angioplasty balloons market. These procedures offer advantages such as shorter recovery times, reduced risk of complications, and less post-operative pain compared to traditional surgeries. Angioplasty balloons, particularly those used in coronary artery bypass grafting (CABG) and other cardiovascular interventions, align with this trend by enabling effective treatment with minimal incisions. For instance, the use of angioplasty balloons for percutaneous coronary interventions (PCIs) is rising globally, driven by patient demand for less invasive treatments. As healthcare systems focus on reducing hospital stays and recovery times, angioplasty balloons are positioned as key tools in enhancing the efficiency and effectiveness of cardiovascular treatments, creating substantial growth opportunities in the market.

• Expanding Applications in Peripheral Artery Disease (PAD) Treatment

Another opportunity for the angioplasty balloons market lies in their growing use for treating peripheral artery disease (PAD). PAD, which affects a significant portion of the aging population, often leads to reduced blood flow to the limbs and can result in severe complications if untreated. Angioplasty balloons are becoming increasingly popular for treating PAD, as they can restore blood flow and improve quality of life with fewer risks than traditional surgeries. Companies like Medtronic have introduced specialized balloon products designed specifically for PAD treatment, catering to the growing number of patients affected by this condition. As PAD continues to rise with an aging population, angioplasty balloons present a key opportunity for expanding into new clinical areas and addressing an unmet medical need.

Restraints/Challenges

• High Cost of Advanced Balloon Technologies

One major restraint in the angioplasty balloons market is the high cost of advanced balloon technologies, especially drug-eluting balloons (DEBs). While DEBs offer superior performance in reducing restenosis, their higher cost compared to traditional balloon angioplasty devices limits their widespread adoption, particularly in cost-sensitive markets. Healthcare providers may opt for standard angioplasty balloons to keep treatment costs lower, especially in regions with budget constraints or lower reimbursement rates. For instance, in many developing countries, the adoption of DEBs is slower due to their higher price point, limiting their penetration despite their clinical benefits. As a result, the high cost of advanced angioplasty balloons remains a significant barrier to market growth, preventing broader accessibility for patients in certain regions.

• Risk of Complications and Procedural Failures

A key challenge faced by the angioplasty balloons market is the risk of complications and procedural failures. Despite being minimally invasive, angioplasty procedures still carry risks, such as vessel rupture, restenosis, or blood clot formation. In some cases, patients may experience adverse reactions to the balloons, particularly with high-pressure or non-compliant devices. For instance, balloon angioplasty can cause damage to the artery's inner lining, leading to complications like dissection or embolism, which can hinder the success of the procedure. The risk of such complications requires skilled professionals and careful patient selection, presenting a challenge to the broader adoption of angioplasty balloon treatments.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Angioplasty Balloons Market Scope

The market is segmented on the basis of type, material, balloon type, disease indication and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Plain Old Balloon Angioplasty
• Drug-Coated Balloon (DCB) Angioplasty
• Cutting Balloons
• Scoring Balloons
• Stent Graft Balloon Catheter

Material

• Nylon
• Polyurethane
• Silicone Urethane Co-Polymers
• Other

Balloon Type

• Semi-Compliant
• Non-Compliant

Disease Indication

• Coronary Angioplasty
• Venous Angioplasty
• Carotid Angioplasty
• Renal Artery Angioplasty
• Peripheral Angioplasty

End User

• Cath Labs
• Hospitals
• Specialty Clinics
• Ambulatory Surgery Centers
• Diagnostic Centers

Angioplasty Balloons Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, material, balloon type, disease indication and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the angioplasty balloons market due to its well-established healthcare infrastructure, high adoption of advanced medical technologies, and a large patient pool suffering from cardiovascular diseases. The U.S. particularly accounts for a significant share of the market, driven by a high prevalence of coronary artery diseases, an aging population, and the increasing preference for minimally invasive procedures. In addition, the presence of major medical device manufacturers, such as Medtronic and Boston Scientific, further supports the market's growth in this region. The U.S. Food and Drug Administration's (FDA) approval of advanced balloon technologies, such as drug-eluting balloons (DEBs), has also fueled their adoption in the region.

The Asia Pacific region is expected to exhibit the highest growth rate in the angioplasty balloons market. This is due to several factors, including the increasing prevalence of cardiovascular diseases, rising healthcare expenditures, and a large and aging population in countries like China and India. In addition, improving healthcare infrastructure, growing awareness of advanced medical treatments, and the adoption of minimally invasive surgical procedures are contributing to the region's market expansion. The rising demand for cost-effective yet advanced medical technologies, such as drug-eluting balloons, is further driving growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Angioplasty Balloons Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Angioplasty Balloons Market Leaders Operating in the Market Are:

• Artivion, Inc (U.S.)
• Balton (Poland)
• Medtronic (U.S.)
• BD (U.S.)
• Boston Scientific Corporation (U.S.)
• Abbott (U.S.)
• AngioDynamics (U.S.)
• B. Braun SE (Germany)
• Biomerics (U.S.)
• Freudenberg Medical (U.S.)
• Biotronik (Germany)
• Cook (U.S.)
• Cardinal Health (U.S.)
• JOTEC GmbH (Germany)
• CTK biotech, Inc. (U.S.)
• Koninklijke Philips N.V. (The Netherlands)
• MicroPort Scientific Corporation (China)
• Nipro Medical Corporation (Japan)
• Stryker (U.S.)
• Teleflex Incorporated (U.S.)
• Terumo Corporation (Japan)

Latest Developments in Angioplasty Balloons Market

• In July 2024, Teleflex Incorporated announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Ringer Perfusion Balloon Catheter (PBC), the only commercially available Percutaneous Transluminal Coronary Angioplasty (PTCA) perfusion balloon. The Ringer™ PBC is a rapid-exchange catheter, compatible with 0.014” guidewires, featuring a distinctive helical balloon at its working end. When inflated, the balloon takes the shape of a hollow cylinder with a large central perfusion lumen
• In March 2024, Boston Scientific Corporation announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its AGENT Drug-Coated Balloon (DCB), designed to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR refers to the narrowing or blockage of a stented vessel due to plaque buildup or scar tissue
• In August 2023, Shanghai MicroPort Medical (Group) Co., Ltd. announced that its Firefighter NC Pro PTCA Balloon Catheter (Firefighter NC Pro) had received market authorization from the U.S. Food and Drug Administration (FDA). The Firefighter NC Pro is designed to improve myocardial perfusion and is intended for balloon dilation of narrowed coronary arteries or coronary artery bypass grafts. It is also suitable for post-dilation following stent implantation. The Firefighter NC Pro features a three-layer composite material design for the balloon, with a maximum rated burst pressure of up to 22 atmospheres
• In June 2023, Cook Medical announced the addition of new size options and locations for its Advance Serenity hydrophilic percutaneous transluminal angioplasty balloon catheter product line. This device, used by interventionalists in both below- and above-the-knee procedures, helps treat patients with peripheral artery disease (PAD). The catheter is produced by Surmodics and distributed by Cook Medical
• In June 2022, Royal Philips revealed the latest findings from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial. The results showed that Philips' Tack (4F) endovascular system, the first and only device of its kind approved by the U.S. Food and Drug Administration (FDA), offers a lasting treatment effect and a positive impact on the quality of life for patients with critical limb ischemia (CLI), a severe form of peripheral arterial disease (PAD), over a three-year clinical follow-up period

SKU-23488